Legend # = co-authors, $ = co-corresponding author

​

20. Yao H, Li C, Brosseau JP, Wang H, Lu H, Fang C, Shi H, Lan J and Xu J. Palmitoylation is critically required for cancer intrinsic PD-1 expression and functions. (revision requested in Science Signaling).

19. Brosseau JP$, Liao CP and Le LQ$. – Translating current basic research into future therapies for Neurofibromatosis type I (revision requested in British Journal of Cancer).

18. Brosseau JP. Chapter 11. Regulation on mRNA: Nodes and Wires. Springer Nature – Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy. Editor: Jie Xu. 2020 (in press).

17. Brosseau JP$ and Le LQ$. Heterozygous Tumor Suppressor Microenvironment in Cancer Development. Trends in Cancer 2019(9):541-6.

16. Yao H#, Lan J#, Li C#, Shi H#, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, Zhou X, Wang C, Xue Y, Cui Y and Xu J. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nature Biomedical Engineering 2019;3(4):306-17.

15. Chen Z, Mo J#, Brosseau JP#, Shipman T, Wang Y, Liao CP, Allaway RJ, Gosline SJC, Guinney J and Le LQ. Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway. Cancer Discovery 2019;9(1):114-29.

14. Brosseau JP. Splicing Isoform-Specific Functional Genomic in Cancer Cells. Applied Cancer Research 2018;38:18.

13. Brosseau JP#, Liao CP#, Wang Y, Ramani V, Vandergriff T, Lee M, Patel A, Ariizumi K and Le LQ. NF1 Heterozygosity Fosters de Novo Tumorigenesis, but Impairs Malignant Transformation. Nature Communications 2018;9(1).

12. Liao CP, Booker R, Brosseau JP, Chen Z, Mo J, Tchegnon E, Wang Y, Clapp W, and Le LQ. Contribution of Inflammation and Tumor Microenvironment to Neurofibroma Tumorigenesis. Journal of Clinical Investigation 2018;128(7):2848-61.

11. Brosseau JP#, Pichard DC#, Legius E, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma S, Brownell I, and Le LQ. The Biology of Cutaneous Neurofibroma. Neurology 2018;91(Suppl 1):S14-20.

10. Brosseau JP, Lucier JF, Lamarche AA, Shkreta L, Gendron D, Lapointe E, Thibault P, Paquet E, Perreault JP, Elela SA, and Chabot B. Redirecting Splicing With Interfering and Stimulating Bifunctional Oligonucleotides. Nucleic Acids Research 2014;42(6):e40.

9. Brosseau JP, Lucier JF, Nwilati H, Thibault P, Garneau D, Gendron D, Durand M, Couture S, Lapointe E, Prinos P, Klinck R, Chabot B, Perreault JP, and Elela SA. Tumor Microenvironment Associated Modifications of Alternative Splicing. RNA 2014;20(2):189-201.

8. Lecka J, Gillerman I, Fausther M, Salem M, Munkonda MN, Brosseau JP, Cadot C, Martín-Satué M, d'Orléans-Juste P, Rousseau E, Poirier D, Künzli B, Fischer B, Sévigny J. 8-BuS-ATP Derivatives as Specific NTPDase1 Inhibitors. British Journal of Pharmacology 2013;169(1):179-96.

7.  Brosseau JP and Elela SA. Chapter 15 - The Merit of Alternative Messenger RNA Splicing as a New Mine for the Next Generation Ovarian Cancer Biomarkers. INTECH Ovarian Cancer – A clinical and translational update. Editor: Ivan Diaz-Padilla. 2013 Feb.

6. Venables JP, Brosseau JP, Gadea G, Klinck R, Prinos P, Beaulieu JF, Lapointe E, Durand M, Thibault P, Tremblay K, Rousset F, Tazi J, Elela SA, and Chabot B. RBFOX2 Enforces the Mesenchymal Splicing Signature in Normal and Cancer Tissues. Molecular and Cellular Biology 2013;33(2):396-405.

5. Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault JP, Wellinger R, and Elela SA. Alternative Splicing of SYK Regulates Mitosis and Cell Survival. Nature Structural & Molecular Biology 2011;18(6):673-9.

4. Brosseau JP#, Lucier JF#, Lapointe E, Durand M, Gendron D, Gervais-Bird J, Tremblay K, Perreault JP, and Elela SA. High-throughput Quantification of Splicing Isoforms. RNA 2010;16(2):442-9.

3. Brosseau JP, Neugebauer WA, Gobeil F Jr, D'Orléans-Juste P. Design, Synthesis, and Pharmacological Characterization of Fluorescein-derived Endothelin Antagonists Bq-123 and Bq-788. Advances in Experimental Medicine and Biology 2009;611:443-4.

2. Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, Gendron D, Brosseau JP, Thibault P, Lucier JF, Tremblay K, Prinos P, Wellinger RJ, Chabot B, Rancourt C, and Elela SA. Identification of Alternative Splicing Markers for Breast Cancer. Cancer Research 2008;68(22):9525-31.

1. Brosseau JP, D'Orléans-Juste P, Neugebauer WA. Development of an Efficient Strategy for the Synthesis of the ETB Receptor Antagonist BQ-788 and Some Related Analogues. Peptides 2005;26(8):1441-53.